Fluvoxamine alleviates paclitaxel-induced neurotoxicity  by Tanimukai, Hitoshi & Kudo, Takashi
Biochemistry and Biophysics Reports 4 (2015) 202–206Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
Abbre
ducer X
homolo
voxamin
1R, sigm
protein
n Corr
Medicin
City, Ky
E-mjournal homepage: www.elsevier.com/locate/bbrepFluvoxamine alleviates paclitaxel-induced neurotoxicity
Hitoshi Tanimukai a,b,n, Takashi Kudo c
a Department of Clinical Oncology, Pharmacogenomics, and Palliative Medicine, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Japan
b Palliative Care Center, Department of Palliative Medicine, Kyoto University Hospital, 54 Kawaharacho, Syogoin, Sakyou-ku, Kyoto City, Kyoto 606-8507,
Japan
c Department of Psychiatry, Osaka University Health Care Center, 1-17, Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japana r t i c l e i n f o
Article history:
Received 4 May 2015
Received in revised form
15 September 2015
Accepted 21 September 2015
Available online 25 September 2015
Keywords:
Chemobrain
Paclitaxel
Endoplasmic reticulum stress
Fluvoxamine
Sigma 1 receptor
Selective serotonin reuptake inhibitorx.doi.org/10.1016/j.bbrep.2015.09.014
08/& 2015 The Authors. Published by Elsevier
viations: BiP, immunoglobulin heavy-chain b
; CACI, chemotherapy-associated cognitive im
gous protein; CYP, cytochrome P450; ER, end
e; JNK, c-Jun NH2-terminal kinase; Px, paclit
a 1 receptor; SSRI, selective serotonin reupta
response
esponding author at: Palliative Care Cente
e, Kyoto University Hospital, 54 Kawaharach
oto 606-8507, Japan. Fax: þ81 757514423.
ail address: tanimuki@kuhp.kyoto-u.ac.jp (H.a b s t r a c t
Paclitaxel (Px) is an effective chemotherapeutic agent for the treatment of various cancers. However, it is
often associated with neurological side effects, including chemotherapy-associated cognitive impairment
(CACI), such as “chemobrain”. Previously, we reported that endoplasmic reticulum (ER) stress is involved
in Px-induced neurotoxicity, and immunoglobulin heavy chain binding protein (BiP) inducer X (BIX)
alleviates Px-induced neurotoxicity. However, BIX has not been used in clinical practice yet. We recently
reported that ﬂuvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R). The
purpose of this study was to investigate whether Flv could alleviate Px-induced neurotoxicity in vitro. SK-
N-SH cells were pre-treated for 12 h with or without 10 μg/ml Flv followed by treatment with 1 μM Px
with or without co-existence of 10 μg/ml Flv for 24 h. To investigate the involvement of Sig-1R in alle-
viation effect on Px-induced neurotoxicity,1 μM NE100, an antagonist of Sig-1R, was added for 24 h.
Neurotoxicity was assessed using the MTS viability assay and ER stress-mediated neurotoxicity was
assessed by evaluating the expression of C/EBP homologous protein (CHOP), cleaved caspase 4, and
cleaved caspase 3.
Pre-treatment with Flv signiﬁcantly alleviated the induction of CHOP, cleaved caspase 4, and cleaved
caspase 3 in SK-N-SH cells. At the same time, pre-treatment with Flv signiﬁcantly induced Sig-1R in SK-
N-SH cells. In addition, viability was signiﬁcantly higher in Flv-treated cells than in untreated cells, which
was reversed by treatment with NE100.
Our results suggest that Flv alleviates Px-induced neurotoxicity in part through the induction of Sig-
1R. Our ﬁndings should contribute to one of the novel approaches for the alleviation of Px-induced
neurotoxicity, including chemobrain.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer treatments, including chemotherapy, radiation therapy,
and targeted biological therapies, have made great advances in the
last century and have led to improved survival. However, their
administration is often associated with several side effects and
may reduce patient quality of life (QOL). Cognitive impairment is
among the most frequently reported problems by patients duringB.V. This is an open access article u
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Tanimukai).the treatment, especially in the context of chemotherapy. This
cognitive impairment related to chemotherapy is known as “che-
mofog” or “chemobrain” and is well studied in breast cancer pa-
tients. Reports demonstrate that 15–75% of breast cancer survivors
have cognitive impairment in the domain of memory, processing
speed, attention, and executive function [1–4]. Multiple hy-
potheses exist regarding chemobrain, including disruption of
hippocampal cell proliferation and neurogenesis [5], chronic in-
creases in inﬂammation [6,7], increased oxidative stress [6], white
matter disruption [8,9], and long-term changes in cerebral blood
ﬂow and metabolism [10]. However, a detailed mechanism and
intervention for CACI have not been established.
Paclitaxel (Px) is a taxane agent that binds microtubules, sta-
bilizes microtubule dynamics, and arrests the cell at the mitotic
phase [11]. However, Px often induces side effects such as ar-
thralgia, myalgia, and ataxia. In addition, pronounced emotional
distress, including depression, and reduced mental QOL through
adjuvant treatment has recently been reported [12]. Though, it isnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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positron emission tomography study demonstrated detectable le-
vels of radiolabeled Px in the brain after intravenous administra-
tion [13], indicating that Px may directly inﬂuence the central
nervous system.
The endoplasmic reticulum (ER) stress response, also called the
unfolded protein response (UPR), is a defense system that deals
with the accumulation of unfolded proteins in the ER lumen.
However, when ER stress is very severe, cells induce and/or acti-
vate C/EBP homologous protein (CHOP), the c-Jun NH2-terminal
kinase (JNK) pathway, and caspase 4, which lead to apoptosis.
Accumulating evidence demonstrates the importance of ER stress
and of UPR in the pathophysiology of human neurological dis-
eases, such as Parkinson's disease [14,15], Alzheimer's disease [15–
18], and causes of cognitive dysfunction. Recently, we reported
that ER stress is involved in Px-induced neurotoxicity [19]. In ad-
dition, we have also reported that immunoglobulin heavy-chain
binding protein (BiP) inducer X (BIX) attenuates Px-induced neu-
rotoxicity through alleviation of ER stress [19]. The effect of BIX in
the alleviation of ER stress has been reported in many other si-
tuations [20–25]. However, BIX has not been approved for clinical
practice use yet and is only permitted for experimental use. Thus,
the exploration of agents like BIX in drugs that have already been
licensed for the clinical setting should be fast way to practical use.
Recently, we reported that ﬂuvoxamine (Flv), a selective ser-
otonin reuptake inhibitor (SSRI) that is widely used in clinical
practice as an antidepressant, alleviates ER stress in vitro and in
animal experiments [26].
In the present study, we investigated the effect of Flv on Px-
induced neurotoxicity using SK-N-SH cells in vitro.2. Materials and methods
2.1. Chemicals
Flv (Sigma-Aldrich, St. Louis, MO, USA) and NE100 (Santa Cruz
Biotechnology, Dallas, Texas, USA) were dissolved in double-dis-
tilled water (DDW). Px (Sigma) was dissolved in dimethyl sulf-
oxide (DMSO).
2.2. Cell culture
SK-N-SH neuroblastoma cells were grown in Dulbecco's Mod-
iﬁed Eagle's Medium (DMEM; GIBCO/Invitrogen Life Technologies,
Paisley, UK) with 10% fetal bovine serum (FBS; JRH, Woodland, CA,
USA). Cells were maintained at 37 °C in an incubator within an
atmosphere of 5% carbon dioxide (CO2). Cells were routinely pas-
saged using trypsin (0.25%)–EDTA (0.1%) solution in Hank's Ba-
lanced Salt Solution (HBSS; Himedia Laboratories Pvt. Ltd., Mum-
bai, India).
2.3. MTS cell viability assays
Cellular viability was assessed using CellTiter 96 Aqueous One
Solution Cell Proliferation Assays (Promega, Madison, WI, USA).
Brieﬂy, SK-N-SH cells were seeded in 96-well plates. Cells were
allowed to attach for 24 h. For evaluation of the toxicity of Flv on
SK-N-SH cells, cells were treated with 10, 25, 50, 75, or 100 μg/ml
Flv for 24 h at 37 °C. For evaluation of the alleviation effect of Flv
on Px-induced neurotoxicity, SK-N-SH cells were pre-treated with
or without 10 μg/ml Flv for 12 h followed by 1 μM Px treatment
with or without 10 μg/ml Flv for 24 h. To conﬁrm the involvement
of Sig-1 R in alleviation effect on Px- induced neurotoxicity, SK-N-
SH cells were incubated with 1 μM Px, 10 μg/ml Flv and 1 μM
NE100 for 24 h. Next, 20 μl of MTS reagent was added to each welland cells were incubated for 2 h. Optical density was measured at
490 nm using a Micro Plate Reader (Bio-Rad, Hercules, CA, USA).
2.4. Western blots
SK-N-SH cells were pre-treated with or without 10 μg/ml Flv
for 12 h followed by 1 μM Px treatment with or without 10 μg/ml
Flv for 24 h at 37 °C. Cells were washed in Tris-buffered saline
(TBS), harvested, and lysed in RIPA buffer (Thermo Fisher Scien-
tiﬁc, Inc., Rockford, IL, USA) with a protease inhibitor cocktail
(Roche, Mannheim, Germany), and a phosphatase inhibitor cock-
tail (Roche). Lysates were sonicated on ice three times for ﬁve
seconds each, and then incubated for 15 min. After centrifugation
for 20 min at 13,000 g, supernatants were retained and boiled in
SDS sample buffer. Lysates (10 μg) were separated on SDS-poly-
acrylamide gels and transferred to polyvinylidene ﬂuoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). Non-speciﬁc protein
binding was blocked by incubating membranes for 1 h at room
temperature in 5% w/v non-fat milk powder in TBS-T [50 mM Tris–
HCl (pH 7.6), 150 mM NaCl, and 0.1% v/v Tween-20]. The mem-
branes were incubated overnight at 4 °C with the following pri-
mary antibodies: anti-CHOP (1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-caspase 4 (1:500; Medical and Biological
laboratories, Nagoya, Japan), anti-caspase 3 (1:1000; Cell Signaling
Technology, Boston, MA, USA), anti-sigma 1 receptor (Sig-1R)
(1:250; Abcom, Cambridge, UK) and anti-GAPDH (1:1000; Thermo
Fisher Scientiﬁc, Waltham, MA, USA). The membranes were then
washed three times in TBS-T for 5 min. Finally, the membranes
were incubated for 60 min at room temperature with HRP-con-
jugated anti-rabbit or anti-mouse antibodies (Promega, Madison,
WI, USA). Protein bands were detected using the ECL Plus kit (GE
Healthcare, Buckinghamshire, UK). The intensity of each band was
quantiﬁed using NIH image J software.
2.5. Statistical analyses
Data are presented as mean values7standard deviation (SD).
Unpaired student's t-test or one-way analysis of variance (ANOVA)
followed by Tukey–Kramer test were used to determine the levels
of signiﬁcance between sample means. All results are re-
presentative of at least three independent experiments.3. Results
3.1. Flv toxicity on SK-N-SH cells
The toxicity of Flv on SK-N-SH cells was examined using an
MTS assay. We used 10, 25, 50, 75, or 100 μg/ml Flv or a vehicle
control to treat SK-N-SH cells. SK-N-SH cells treated with Flv
showed 80% (25 μg/ml), 29% (50 μg/ml), 19% (75 μg/ml), and 18%
(100 μg/ml) viability compared to the vehicle control cells
([po0.001] at all doses) (Fig. 1). However, SK-N-SH cells treated
with 10 μg/ml Flv did not show reduced viability (102%) compared
to the vehicle control (Fig. 1). Based on these data, we used 10 μg/
ml Flv in all subsequent experiments.
3.2. Flv alleviates Px-induced ER stress mediated apoptosis
Next we investigated whether Flv could alleviate Px-induced
ER stress-mediated apoptosis in SK-N-SH cells by monitoring
CHOP, cleaved caspase 4, and cleaved caspase 3, an active form of
each caspase. CHOP, cleaved caspase 4, and cleaved caspase 3 were
induced in cells treated with Px compared to control cells (Fig. 2a–
c, [po0.01] at each comparison), which is consistent with our
previous report [19], On the other hand, when cells were pre-
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Fig. 1. Flv toxicity in SK-N-SH cells. Flv was added to SK-N-SH cells at the indicated
dose. Cell toxicity was assessed using an MTS assay 24 h later. DDW was applied as
the vehicle control. The relative ratio compared with the absorbance of the vehicle
control (0 μM) is indicated. Histograms shows the mean7SD from six independent
experiments. npo0.001 (Student's t-test).
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induction of CHOP, cleaved caspase 4 and cleaved caspase 3 were
alleviated compared to the Flv-untreated cells (Fig. 2a–c, po0.05,
po0.05, and po0.01, respectively). We next investigated the in-
duction of Sig-1R by Flv in SK-N-SH cells. Flv has been reported not
only as a potent Sig-1R agonist with stronger afﬁnity than other
SSRIs [27], but also as an inducer of Sig-1R [26]. Sig-1R was in-
duced in cells treated with Flv for 12 h compared to untreated cells
(Fig. 2d, po0.05). This induction continued for at least 24 h
(Fig. 2e, po0.01).
3.3. Flv alleviates Px-induced neurotoxicity through Sig-1R
Finally, using a MTS assay, we quantitatively assessed whether
Flv can alleviate Px-induced neurotoxicity. Similar to the results
from Western blots, the viability that was decreased by Px treat-
ment was recovered in Flv-pre-treated cells compared to Flv-un-
treated cells (Fig. 3, po0.05). This recovery was reversed when
cells were incubated with Px, Flv and NE100 (Fig. 3, po0.05).4. Discussion
In the present study, we investigated the neuroprotective ef-
fects of Flv on Px-induced neurotoxicity. We have clearly demon-
strated that Flv alleviates the Px-induced ER stress-mediated
apoptosis. We have also shown that the alleviation effect of Flv isdue to the possible involvement of Sig-1R induction that is char-
acteristic in Flv. These data suggest that Flv may be a candidate
drug for the alleviation of Px-induced neurological side effects.
We have shown that a low dose of Flv (10 μg/ml) does not af-
fect the viability of SK-N-SH cells. On the other hand, viability in
both cells gradually decreases in a dose- dependent manner. Re-
cently, the possible anti-cancer properties of antidepressants, in-
cluding SSRIs, was reported, and increased interest within the
scientiﬁc community [28–30]. Our results from experiments using
a high dose of Flv (≧25 μg/ml) correspond with previous reports.
Px is a taxane agent and neurotoxicity is one of its most pro-
minent side effects, leading to peripheral neuropathy in many
patients. On the other hand, Px could also cause pronounced
emotional distress, including depression [12], and/or cognitive
dysfunction because detectable levels of radiolabeled Px was
found in the brain by a positron emission tomography [13]. Several
putative hypotheses regarding Px-induced neurotoxicity, such as
abnormal aggregation of microtubules in neuronal cells and direct
injury of neuronal cells through intrinsic toxicity are being con-
sidered. We have previously reported that Px-induced ER stress
mediates neuronal apoptosis and BIX attenuates its neurotoxicity
through alleviation of ER stress [19]. In the present study, we have
demonstrated that pre-treatment with 10 μg/ml Flv, instead of
BIX, signiﬁcantly alleviates Px-induced CHOP, cleaved caspase 4,
and cleaved caspase 3 (Fig. 2a–c). These results indicate that Flv
alleviates Px-induced ER stress-mediated apoptosis. This tendency
was also seen in the results of the MTS assay (Fig. 3). A similar
result has been reported in human neuroblastoma SH-SY5Y cells
treated with tunicamycin, an ER stress-inducing reagent [31].
However, the authors did not suggest how Flv alleviates ER stress.
Recently, we have reported that Flv alleviates ER stress via in-
duction of Sig1-R [26]. Sig-1R, which is expressed on ER mem-
branes, has recently been discovered and shown to have neuro-
protective activity as a molecular chaperone regulating protein
folding and degradation at the ER [32–35]. Furthermore, growing
evidence suggests that Sig-1R plays an important role in neuronal
plasticity, a process implicated in the pathophysiology of neu-
ropsychiatric diseases, such as major depressive disorder and
schizophrenia. Thus, Sig-1R receptor may be a novel therapeutic
target for neuropsychiatric diseases and disorders [36–39]. Similar
to that of our previous report, the expression of Sig-1R was in-
duced in SK-N-SH cells treated by 10 μg/ml Flv after 12 h (Fig. 2d)
and the induction continued for at least 24 h (Fig. 2e). In addition,
the alleviation effect of Flv on Px-induced neurotoxicity was re-
versed by NE100 (Fig. 3). Based on our previous and present re-
sults, Sig-1R is involved in the alleviation of Px-induced
neurotoxicity.
Previous study demonstrated that Px-treated mice exhibit
mechanical allodynia on days 3–15 of Px administration [40]. In-
terestingly, Flv administration for 5 days weakly but signiﬁcantly
attenuated Px-induced allodynia. Although, we only performed a
cellular model and focused on the Px induced ER stress related
neurotoxicity in the present study, our previous animal study has
demonstrated that Flv treatment suppressed cerebral infarction
size in mice after focal cerebral ischemia [26]. Because cerebral
ischemia also induces ER stress [41], Flv could alleviate Px induced
ER stress related neurotoxicity in the brain. Further in vivo studies,
including cognitive behavioral evaluation in Px-injected mice, are
needed to support our study.
In conclusion, we have shown that Flv alleviates Px-induced
neurotoxicity in vitro and Sig-1R is involved in this alleviation
mechanism. Flv has been commonly used in clinical practice, in-
cluding in patients with breast cancer. Thus, a detailed evaluation
of Flv effects (not only on depression but also other neurological
symptoms, including cognitive function) will be required in clin-
ical practice for the numerous applicable symptoms.
CHOP Caspase 4
Full
Cleaved Caspase 3
Full
Cleaved
GAPDH GAPDH GAPDH
C P
x
P
x
+ 
Fl
v
C P
x
P
x
+ 
Fl
v
C P
x
P
x
+ 
Fl
v
** * ** * ***
C
on
tro
l
Fl
v 
(1
2h
)  
Sig-1 R
GAPDH
C
on
tro
l
Fl
v 
(2
4h
)  
Sig-1 R
GAPDH
*
R
el
at
iv
e 
ra
tio
**
R
el
at
iv
e 
ra
tio
R
el
at
iv
e 
ra
tio
R
el
at
iv
e 
ra
tio
R
el
at
iv
e 
ra
tio
Fig. 2. Flv alleviates Px-induced ER stress-mediated apoptosis. (a–c) SK-N-SH cells were pre-treated with or without 10 μg/ml Flv for 12 h followed by a 1-μM Px treatment
with or without 10 μg/ml Flv for 24 h. CHOP, caspase 4, and caspase 3 were detected by Western blotting. GAPDH was used as an internal control. npo0.05, nnpo0.01 (one-
way ANOVA followed by Tukey–Kramer test. (d and e) SK-N-SH cells were treated with 10 μg/ml Flv for 12 h and 24 h. Sig-1R was detected by Western blotting. GAPDH was
used as an internal control. npo0.05, nnpo0.01 (Student's t-test).
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Fig. 3. Flv alleviates Px-induced neurotoxicity through Sig-1R. SK-N-SH cells were
pre-treated with or without 10 μg/ml Flv for 12 h followed by a 1 μM Px, 10 μg/ml
Flv, and 1 μM Px/10 μg/ml Flv, with or without 1 μM NE100 treatment for 24 h. The
viability was assessed using an MTS assay. The relative ratio of the absorbance
compared with the vehicle control absorbance is indicated. Histograms show the
mean7SD from six independent experiments. *po0.05, **po0.01 (one-way AN-
OVA followed by Tukey–Kramer test).
H. Tanimukai, T. Kudo / Biochemistry and Biophysics Reports 4 (2015) 202–206 205Acknowledgments
We thank Ms. Mieko Kitamura for technical assistance. This
work was supported by a Grant-in-Aid for Scientiﬁc Research (C)
(25461729) from the Ministry of Education, Culture, Sports, Sci-
ence, and Technology of Japan.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2015.09.014.References
[1] T.A. Ahles, A.J. Saykin, C.T. Furstenberg, B. Cole, L.A. Mott, K. Skalla, M.
B. Whedon, S. Bivens, T. Mitchell, E.R. Greenberg, P.M. Silberfarb, Neu-
ropsychologic impact of standard-dose systemic chemotherapy in long-term
survivors of breast cancer and lymphoma, J. Clin. Oncol. 20 (2002) 485–493.
[2] C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston, I.F. Tannock, Cognitive
function in breast cancer patients receiving adjuvant chemotherapy, J. Clin.
Oncol. 18 (2000) 2695–2701.
[3] F. Joly, O. Rigal, S. Noal, B. Giffard, Cognitive dysfunction and cancer: which
consequences in terms of disease management? Psychooncology 20 (2011)
1251–1258.
[4] S.B. Schagen, F.S. van Dam, M.J. Muller, W. Boogerd, J. Lindeboom, P.F. Bruning,
Cognitive deﬁcits after postoperative adjuvant chemotherapy for breast car-
cinoma, Cancer 85 (1999) 640–650.
[5] M. Monje, J. Dietrich, Cognitive side effects of cancer therapy demonstrate a
functional role for adult neurogenesis, Behav. Brain Res. 227 (2012) 376–379.
[6] C.D. Aluise, S. Miriyala, T. Noel, R. Sultana, P. Jungsuwadee, T.J. Taylor, J. Cai, W.
M. Pierce, M. Vore, J.A. Moscow, D.K. St Clair, D.A. Butterﬁeld, 2-Mercap-
toethane sulfonate prevents doxorubicin-induced plasma protein oxidation
and TNF-alpha release: implications for the reactive oxygen species-mediated
mechanisms of chemobrain, Free Radic. Biol. Med. 50 (2011) 1630–1638.
[7] J.S. Myers, The possible role of cytokines in chemotherapy-induced cognitive
deﬁcits, Adv. Exp. Med. Biol. 678 (2010) 119–123.
[8] S.M. Stemmer, J.C. Stears, B.S. Burton, R.B. Jones, J.H. Simon, White matter
changes in patients with breast cancer treated with high-dose chemotherapy
and autologous bone marrow support, AJNR Am. J. Neuroradiol. 15 (1994)
1267–1273.
[9] S. Deprez, F. Amant, A. Smeets, R. Peeters, A. Leemans, W. Van Hecke, J.
S. Verhoeven, M.R. Christiaens, J. Vandenberghe, M. Vandenbulcke, S. Sunaert,
Longitudinal assessment of chemotherapy-induced structural changes in cer-
ebral white matter and its correlation with impaired cognitive functioning, J.
H. Tanimukai, T. Kudo / Biochemistry and Biophysics Reports 4 (2015) 202–206206Clin. Oncol. 30 (2012) 274–281.
[10] D.H. Silverman, C.J. Dy, S.A. Castellon, J. Lai, B.S. Pio, L. Abraham, K. Waddell,
L. Petersen, M.E. Phelps, P.A. Ganz, Altered frontocortical, cerebellar, and basal
ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after
chemotherapy, Breast Cancer Res. Treat. 103 (2007) 303–311.
[11] M.A. Jordan, L. Wilson, Microtubules and actin ﬁlaments: dynamic targets for
cancer chemotherapy, Curr. Opin. Cell Biol. 10 (1998) 123–130.
[12] L.M. Thornton, W.E. Carson 3rd, C.L. Shapiro, W.B. Farrar, B.L. Andersen, De-
layed emotional recovery after taxane-based chemotherapy, Cancer 113
(2008) 638–647.
[13] A. Gangloff, W.A. Hsueh, A.L. Kesner, D.O. Kiesewetter, B.S. Pio, M.D. Pegram,
M. Beryt, A. Townsend, J. Czernin, M.E. Phelps, D.H. Silverman, Estimation of
paclitaxel biodistribution and uptake in human-derived xenografts in vivo
with (18)F-ﬂuoropaclitaxel, J. Nucl. Med. 46 (2005) 1866–1871.
[14] J.J. Hoozemans, E.S. van Haastert, P. Eikelenboom, R.A. de Vos, J.M. Rozemuller,
W. Scheper, Activation of the unfolded protein response in Parkinson’s disease,
Biochem. Biophys. Res. Commun. 354 (2007) 707–711.
[15] J.J. Hoozemans, E.S. van Haastert, D.A. Nijholt, A.J. Rozemuller, W. Scheper,
Activation of the unfolded protein response is an early event in Alzheimer’s
and Parkinson’s disease, Neurodegener. Dis. 10 (2012) 212–215.
[16] T. Katayama, K. Imaizumi, N. Sato, K. Miyoshi, T. Kudo, J. Hitomi, T. Morihara,
T. Yoneda, F. Gomi, Y. Mori, Y. Nakano, J. Takeda, T. Tsuda, Y. Itoyama,
O. Murayama, A. Takashima, P. George-Hyslop St, M. Takeda, M. Tohyama,
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-
protein response, Nat. Cell Biol. 1 (1999) 479–485.
[17] T. Kudo, M. Okumura, K. Imaizumi, W. Araki, T. Morihara, H. Tanimukai,
E. Kamagata, N. Tabuchi, R. Kimura, D. Kanayama, A. Fukumori, S. Tagami,
M. Okochi, M. Kubo, H. Tanii, M. Tohyama, T. Tabira, M. Takeda, Altered loca-
lization of amyloid precursor protein under endoplasmic reticulum stress,
Biochem. Biophys. Res. Commun. 344 (2006) 525–530.
[18] Y. Sakagami, T. Kudo, H. Tanimukai, D. Kanayama, T. Omi, K. Horiguchi,
M. Okochi, K. Imaizumi, M. Takeda, Involvement of endoplasmic reticulum
stress in tauopathy, Biochem. Biophys. Res. Commun. 430 (2013) 500–504.
[19] H. Tanimukai, D. Kanayama, T. Omi, M. Takeda, T. Kudo, Paclitaxel induces
neurotoxicity through endoplasmic reticulum stress, Biochem. Biophys. Res.
Commun. 437 (2013) 151–155.
[20] T. Kudo, S. Kanemoto, H. Hara, N. Morimoto, T. Morihara, R. Kimura, T. Tabira,
K. Imaizumi, M. Takeda, A molecular chaperone inducer protects neurons from
ER stress, Cell Death Differ. 15 (2008) 364–375.
[21] Y. Oida, H. Izuta, A. Oyagi, M. Shimazawa, T. Kudo, K. Imaizumi, H. Hara, In-
duction of BiP, an ER-resident protein, prevents the neuronal death induced by
transient forebrain ischemia in gerbil, Brain Res. 1208 (2008) 217–224.
[22] Y. Inokuchi, Y. Nakajima, M. Shimazawa, T. Kurita, M. Kubo, A. Saito, H. Sajiki,
T. Kudo, M. Aihara, K. Imaizumi, M. Araie, H. Hara, Effect of an inducer of BiP, a
molecular chaperone, on endoplasmic reticulum (ER) stress-induced retinal
cell death, Investig. Ophthalmol. Vis. Sci. 50 (2009) 334–344.
[23] S. Hino, S. Kondo, K. Yoshinaga, A. Saito, T. Murakami, S. Kanemoto, H. Sekiya,
K. Chihara, Y. Aikawa, H. Hara, T. Kudo, T. Sekimoto, T. Funamoto, E. Chosa,
K. Imaizumi, Regulation of ER molecular chaperone prevents bone loss in a
murine model for osteoporosis, J. Bone Miner. Metab. 28 (2010) 131–138.
[24] Y. Oida, J. Hamanaka, K. Hyakkoku, M. Shimazawa, T. Kudo, K. Imaizumi,T. Yasuda, H. Hara, Post-treatment of a BiP inducer prevents cell death after
middle cerebral artery occlusion in mice, Neurosci. Lett. 484 (2010) 43–46.
[25] T. Nakanishi, M. Shimazawa, S. Sugitani, T. Kudo, S. Imai, Y. Inokuchi,
K. Tsuruma, H. Hara, Role of endoplasmic reticulum stress in light-induced
photoreceptor degeneration in mice, J. Neurochem. 125 (2013) 111–124.
[26] T. Omi, H. Tanimukai, D. Kanayama, Y. Sakagami, S. Tagami, M. Okochi,
T. Morihara, M. Sato, K. Yanagida, A. Kitasyoji, H. Hara, K. Imaizumi, T. Maurice,
N. Chevallier, S. Marchal, M. Takeda, T. Kudo, Fluvoxamine alleviates ER stress
via induction of Sigma-1 receptor, Cell Death Dis. 5 (2014) e1332.
[27] N. Narita, K. Hashimoto, S. Tomitaka, Y. Minabe, Interactions of selective ser-
otonin reuptake inhibitors with subtypes of sigma receptors in rat brain, Eur. J.
Pharmacol. 307 (1996) 117–119.
[28] C.S. Lee, Y.J. Kim, E.R. Jang, W. Kim, S.C. Myung, Fluoxetine induces apoptosis in
ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-de-
pendent activation of nuclear factor-kappaB, Basic Clin. Pharmacol. Toxicol.
106 (2010) 446–453.
[29] Y. Levkovitz, I. Gil-Ad, E. Zeldich, M. Dayag, A. Weizman, Differential induction
of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evi-
dence for p-c-Jun, cytochrome c, and caspase-3 involvement, J. Mol. Neurosci.
27 (2005) 29–42.
[30] V. Kannen, H. Hintzsche, D.L. Zanette, W.A. Silva Jr., S.B. Garcia, A.M. Waaga-
Gasser, H. Stopper, Antiproliferative effects of ﬂuoxetine on colon cancer cells
and in a colonic carcinogen mouse model, PLoS One 7 (2012) e50043.
[31] T. Hosoi, T. Miyahara, T. Kayano, S. Yokoyama, K. Ozawa, Fluvoxamine atte-
nuated endoplasmic reticulum stress-induced leptin resistance, Front. En-
docrinol. 3 (2012) 12.
[32] T. Hayashi, T. Maurice, T.P. Su, Ca(2þ) signaling via sigma(1)-receptors: novel
regulatory mechanism affecting intracellular Ca(2þ) concentration, J. Phar-
macol. Exp. Ther. 293 (2000) 788–798.
[33] T. Hayashi, T. Su, The sigma receptor: evolution of the concept in neu-
ropsychopharmacology, Curr. Neuropharmacol. 3 (2005) 267–280.
[34] T. Hayashi, T.P. Su, Regulating ankyrin dynamics: Roles of sigma-1 receptors,
Proc. Natl. Acad. Sci. USA 98 (2001) 491–496.
[35] T. Hayashi, T.P. Su, Sigma-1 receptor chaperones at the ER-mitochondrion
interface regulate Ca(2þ) signaling and cell survival, Cell 131 (2007) 596–610.
[36] K. Hashimoto, K. Ishiwata, Sigma receptor ligands: possible application as
therapeutic drugs and as radiopharmaceuticals, Curr. Pharm. Des. 12 (2006)
3857–3876.
[37] T. Hayashi, S.Y. Tsai, T. Mori, M. Fujimoto, T.P. Su, Targeting ligand-operated
chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders,
Expert Opin. Ther. Targets 15 (2011) 557–577.
[38] T. Niitsu, M. Iyo, K. Hashimoto, Sigma-1 receptor agonists as therapeutic drugs
for cognitive impairment in neuropsychiatric diseases, Curr. Pharm. Des. 18
(2012) 875–883.
[39] S.M. Stahl, The sigma enigma: can sigma receptors provide a novel target for
disorders of mood and cognition? J. Clin. Psychiatry 69 (2008) 1673–1674.
[40] S. Katsuyama, K. Sato, T. Yagi, Y. Kishikawa, H. Nakamura, Effects of repeated
milnacipran and ﬂuvoxamine treatment on mechanical allodynia in a mouse
paclitaxel-induced neuropathic pain model, Biomed. Res. 34 (2013) 105–111.
[41] D.J. DeGracia, H.L. Montie, Cerebral ischemia and the unfolded protein re-
sponse, J. Neurochem. 91 (2004) 1–8.
